- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00012376
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
Dose Finding Study of Bryostatin-1 and GM-CSF in Refractory Myeloid Malignancies
Aperçu de l'étude
Statut
Les conditions
- Thrombocytopénie
- Leucémie myélomonocytaire chronique
- Leucémie myéloïde aiguë récurrente de l'adulte
- Leucémie myéloïde aiguë de l'adulte avec anomalies 11q23 (MLL)
- Leucémie myéloïde aiguë de l'adulte avec Del(5q)
- Leucémie myéloïde aiguë de l'adulte avec Inv(16)(p13;q22)
- Leucémie myéloïde aiguë de l'adulte avec t(16;16)(p13;q22)
- Leucémie myéloïde aiguë de l'adulte avec t(8;21)(q22;q22)
- Leucémie myéloïde aiguë non traitée chez l'adulte
- Leucémie myéloïde chronique en phase accélérée
- Leucémie myéloïde chronique en phase chronique
- Syndromes myélodysplasiques précédemment traités
- Leucémie myéloïde chronique récurrente
- Leucémie myéloïde aiguë de l'adulte avec t(15;17)(q22;q12)
- Hémoglobinurie paroxystique nocturne
- Anémie réfractaire
- Leucémie myéloïde chronique en phase blastique
- Anémie réfractaire avec sidéroblastes en couronne
Description détaillée
PRIMARY OBJECTIVES:
I. To determine the maximally tolerated dose of continuous intravenous infusion bryostatin-1 when given in combination with GM-CSF.
II. To describe and quantify the frequency of toxicity of the combination of continuous intravenous infusion bryostatin-1 and subcutaneously administered GM-CSF.
SECONDARY OBJECTIVES:
I. To describe the impact of the combination of bryostatin-1 and GM-CSF on the differentiation and cell cycle distribution of myeloid cells in vivo.
II. To describe the impact of the combination of bryostatin-1 and GM-CSF on T lymphocyte populations.
III. To assess the pharmacokinetics of continuous infusion bryostatin-1.
OUTLINE: This is a dose-escalation study of bryostatin 1.
Patients receive bryostatin 1 IV continuously and sargramostim (GM-CSF) subcutaneously once daily on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with disease stabilization or improvement may continue treatment for up to 12 courses.
Cohorts of 2 patients receive escalating doses of bryostatin 1 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 30% of patients experience dose-limiting toxicity.
PROJECTED ACCRUAL: A maximum of 45 patients will be accrued for this study within 12-18 months.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287-8936
- Johns Hopkins University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- The diagnosis of MDS must be confirmed by a bone marrow aspirate and/or biopsy revealing refractory anemia, or primary refractory leukopenia or thrombocytopenia with morphologic features of MDS; patients with 5q- syndrome are ineligible; patients with RA and RARS are eligible provided they are transfusion dependent. Patients with chronic myelomonocytic leukemia (CMMoL) are eligible; allogeneic BMT will be the treatment priority for patients with HLA-matched siblings; MDS patients for whom intensive chemotherapy has failed to achieve remission will be candidates for this trial if the chemotherapy was administered > 1 month prior to enrollment, and performance status is adequate; patients are also eligible having previously progressed on other institutional trials, including phenylbutyrate and ATRA or 5'-azacytadine
- Patients must have a bone marrow aspirate or biopsy confirmed diagnosis of relapsed AML within 4 weeks of registering for this trial; patients will be eligible only if their WBC is < 30 x 103/:l and stable for at least 7 days, and if they are unlikely to require cytotoxic therapy during the duration of the trial; patients may not have APL
- Newly diagnosed patients may be considered for this trial provided they do not qualify for potentially curative intensive chemotherapeutic regimens; patients with APL are not eligible for this trial; patients who have refused chemotherapy for untreated AML, or who are deemed to be poor candidates medically for AML induction chemotherapy, but otherwise meet the criteria list below may enroll on this trial
- Patients with accelerated or myeloid blast phase CML are eligible if their blast count is < 30 x 103/:L and stable for at least 7 days; patients previously treated for chronic phase CML will be eligible for this protocol; patients may also have undergone treatment for acceleration or blastic phase provided this is not within 2 weeks of enrollment and they meet all the eligibility criteria
- All patients with PNH will be eligible provided they are experiencing symptoms associated with their disease; in particular, patients experiencing life-threatening complications of their illness, including abdominal, central vein or cerebral thromboses, active infections, as well as recurrent, symptomatic hemolytic crises and do not have other treatment options are encouraged to consider participation
- JHOC confirmed and documented diagnosis of either AML, MDS, CML in accelerated or blast phase or PNH
- Patients must have relatively stable bone marrow function for more than ten days prior to enrollment on the study; WBC count doubling within this time period would indicate unstable bone marrow function
- ECOG performance status of 0, 1, 2
- Patients must have central intravenous access; acceptable access include: PICC lines, hickman and hohn catheters, and port-a-caths
- Patient or caregiver must be willing to perform subcutaneous injection
- Serum creatinine < 2.0 mg/dL
- Total serum bilirubin =< 1.6 mg/dL, unless secondary to hemolysis
- SGOT/SGPT each < 2 times the upper limit of normal unless disease related (i.e., PNH, extramedullary disease)
- Hemoglobin should be at least 8 gm/dL at the time of protocol entry; patients may receive transfusions to achieve this level
- Patients must not have received treatment for their myeloid disorder within 2 weeks of beginning the trial; treatments include the use of chemotherapy, hematopoietic growth factors, and biologic therapy such as monoclonal antibodies; the exception is the use of hydroxyurea for patients with WBC > 10 x 103/:L; this duration of time appears adequate for wash out due to the relatively short-acting nature of most anti-leukemia agents
- Patients must have recovered from all toxicities (to grade 0 or 1) associated with previous treatment
- Patients must not have any clinical symptoms of active CNS disease; if CNS disease is suspected, patient must have LP with negative cytology
- Patients must not have evidence of pulmonary leukostasis (i.e., the clinical syndrome associated with symptomatic shortness of breath or hypoxia which is directly attributed to an elevated white blood cell count and the resulting capillary ischemia) or disseminated intravascular coagulation (i.e., the clinical syndrome associated with systemic intravascular clotting which is directly attributed to excessive procoagulants that overwhelm the inhibitory arm of the coagulation cascade)
- All women of potential child bearing must have negative serum B-HCG and use an effective means of birth control throughout the trial period
- Patients must be able to provide informed consent and to return to clinic for adequate follow up as required by the protocol
Exclusion Criteria:
- Diagnosis of RA with 5q- syndrome
- Leukemia with blast count > 30 x 103/:L, uncontrolled with hydroxyurea
- APL
- CML in lymphoid blast phase
- ECOG performance status >= 3
- Patients with untreated positive blood cultures or radiographic evidence of active infections
- Patients with active CNS disease
- Patients with a previous history of intolerance to GM-CSF
- Pregnant or lactating women are not eligible for this protocol; all patients with child-bearing potential must use effective contraception
- Patients who have received bryostatin-1 in the past are not eligible for this protocol
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment (bryostatin 1 and sargramostim)
Patients receive bryostatin 1 IV continuously and GM-CSF subcutaneously once daily on days 1-21.
Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Patients with disease stabilization or improvement may continue treatment for up to 12 courses.
|
Études corrélatives
Études corrélatives
Autres noms:
Étant donné IV
Autres noms:
Administré par voie sous-cutanée
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
MTD defined as the dose at which the CRM estimates that 30% of patients will experience dose-limiting toxicity (DLT) assessed using CTC version 2.0
Délai: 56 days
|
56 days
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: B. Smith, Johns Hopkins University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs par type histologique
- Tumeurs
- Maladies urologiques
- Manifestations urologiques
- Maladies de la moelle osseuse
- Maladies hématologiques
- Troubles myéloprolifératifs
- Troubles urinaires
- Processus néoplasiques
- Troubles des plaquettes sanguines
- Maladies myélodysplasiques-myéloprolifératives
- Protéinurie
- Anémie, hémolytique
- Transformation cellulaire, Néoplasique
- Carcinogenèse
- Syndromes myélodysplasiques
- Leucémie
- Leucémie myéloïde
- Leucémie, myéloïde, aiguë
- Leucémie myélomonocytaire chronique
- Leucémie myélomonocytaire juvénile
- Anémie
- Leucémie, myéloïde, chronique, BCR-ABL positif
- Leucémie, myéloïde, phase chronique
- Thrombocytopénie
- Crise explosive
- Leucémie, myéloïde, phase accélérée
- Hémoglobinurie
- Hémoglobinurie paroxystique
- Anémie réfractaire
- Effets physiologiques des médicaments
- Agents antinéoplasiques
- Facteurs immunologiques
- Adjuvants, immunologique
- Sargramostim
- Bryostatine 1
Autres numéros d'identification d'étude
- NCI-2012-03159
- P01CA015396 (Subvention/contrat des NIH des États-Unis)
- J0051
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .